

Epidemiologic/Correlative

- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- UCI 16-01 SUSPENDED** Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)
- UCI 16-43** Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)
- UCI 17-76**** Variations in Local Microbiome Populations in Normal Colorectal Tissue and Polyps (Whiteson)
- UCI 17-99**** A Blood Test to Predict and Monitor Recurrence of Colorectal Cancers using Integrated Comprehensive Droplet Digital Detection (IC 3D) (Zell)

**Therapeutic - Multi-Site
(Including Colon)**

- UCI 16-96** Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)
- UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)
- SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)


**COLORECTAL
CANCER**

Screening

- UCI 12-40** Atlas Colorectal Health Network (Park)
- UCI 14-30** Low Residue Diet vs. Clear Liquid Diet with Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

Stage IIA/IIIA (T2N1,T3N0,T3N1) Neoadjuvant

SWOG N1048 Phase II/III Trial of Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation VS Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal Excision (Pigazzi)



Stage 0-III Post-Adjuvant

SWOG S0820 Phase IIA Randomized Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer (Zell)

Perioperative

UCI 17-28 Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma (Pigazzi)

Stage IV 2nd Line

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

SWOG S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-Refractory Metastatic Colorectal Cancer (mCRC) (Davvani)